Session Title: 50 Years of Advances in Breast Cancer Treatment: What Have We Learned? Where Are We Going?

Session Type: Education Session

Track: Breast Cancer

Time: 1:00 PM - 2:15 PM

Location: E Hall D1

- 50 Years of Surgery for Breast Cancer: Doing Less?
  
  *Kelly Hunt, MD*

- 50 Years of Radiotherapy for Breast Cancer: Doing More?

  *Jay R. Harris, MD*

- 50 Years of Systemic Therapy for Breast Cancer: From One Size Fits All to Tailored Therapy

  *Harold J. Burstein, MD, PhD - Chair*

- Panel Question and Answer

---

Session Title: Preparing for an Epidemic: Cancer Care in an Aging Population

Session Type: Education Session

Track: Geriatric Oncology

Time: 1:00 PM - 2:15 PM

Location: E253

- Institute of Medicine Recommendations: Looking Back and Moving Forward

  *Arti Hurria, MD - Chair*

- Growing Demand: How to Improve Geriatric Training and Partnership with Primary Care

  *Neil Wenger, MD*

- Rising Costs: How to Maintain Accessible and Affordable Health Care for Elders

  *Ya-Chen T. Shih, PhD*

- Panel Question and Answer
Session Title: Update on Clinical Management of Esophagogastric Cancer
Session Type: Education Session
Track: Gastrointestinal (Noncolorectal) Cancer
Time: 1:00 PM - 2:15 PM
Location: E Arie Crown Theater

- Multimodality Therapy of Locally Advanced Esophagogastric Cancer  
  Barbara Burtness, MD - Chair
- Clinical and Radiographic Risk and Response Assessment in Esophagogastric Cancer  
  David H. Ilson, MD, PhD
- Biomarkers and Novel Agents in Esophagogastric Cancer  
  Syma Iqbal, MD
- Panel Question and Answer

Session Title: Value Assessment of Therapeutic Options in Head and Neck Cancer Care
Session Type: Education Session
Track: Head and Neck Cancer
Time: 1:00 PM - 2:15 PM
Location: E450

- Value Considerations of Systemic Therapy Options  
  David G. Pfister, MD - Chair
- Radiotherapy Modalities and Fractionation: Cost versus Benefit  
  David Sher, MD, MPH
- Can We Personalize Value in Head and Neck Cancer?  
  Jonas A. De Souza, MD
- Panel Question and Answer

Session Title: BRCA Mutation-Associated Breast Cancer: Local and Systemic Treatment Considerations - Ticketed Session
Session Type: Meet the Professor Session
Track: Breast Cancer
Time: 1:00 PM - 2:15 PM
Location: E451a

- BRCA Mutation-Associated Breast Cancer: Local and Systemic Treatment Considerations  
  Susan M. Domchek, MD
Session Title: Celebrating the 50th Anniversary of the Surgeon General's Report on Tobacco: Renewing Our Commitment to Effective Cancer Treatment and Control

Session Type: Extended Education Session

Track: Cancer Prevention/Epidemiology

Time: 1:00 PM - 3:15 PM

Location: S100a

- Tobacco Products and Regulation over the Last 50 Years
  *Kenneth Michael Cummings, PhD - Chair*
- Collating and Presenting the Scientific Evidence for the Surgeon General's Report
  *David Sidransky, MD*
- Evidence for Tobacco Cessation in Cancer Care
  *Graham Walter Warren, MD, PhD*
- Products for Smoking Cessation: Past, Present, and Future
  *Carolyn M. Dresler, MD, MPA*
- How to Implement Smoking Cessation into a Busy Clinical Practice
  *Jamie S. Ostroff, PhD*
- Panel Discussion
  *Stephanie R. Land, PhD*
- Panel Question and Answer

Session Title: Fertility Preservation: State of the Art and Future Directions

Session Type: Extended Education Session

Track: Patient and Survivor Care

Time: 1:00 PM - 3:15 PM

Location: S504

- Developments in Fertility Preservation: The Patient Advocate Perspective
  *Joyce Reinecke, JD - Chair*
- Current Options for Men with Cancer to Preserve Fertility before Treatment
  *John Mulhall, MD*
- Current Options for Women with Cancer to Preserve Fertility before Treatment
  *Jennifer Mersereau, MD, MSCI*
- Pediatric Viewpoint on Fertility Preservation in Patients with Cancer
  *W. H. Wallace, MD*
- Psychologic and Ethical Issues to Consider in Patients Undergoing Fertility Preservation before Cancer Treatment
  *Gwendolyn P. Quinn, PhD*
• New Scientific Horizons in Fertility Preservation for Patients with Cancer
  *Teresa K. Woodruff, PhD*
  • Panel Question and Answer

**Session Title:** Immunology for Nonimmunologists  
**Session Type:** Extended Education Session  
**Track:** Developmental Therapeutics  
**Time:** 1:00 PM - 3:15 PM  
**Location:** E354a

• Cancer Immunology: Basic Principles and Historical Perspectives  
  *Lawrence Fong, MD*
  • Tumor-Host Immune System Interactions: Prognostic and Therapeutic Implications  
  *Sylvia Adams, MD*
  • Principles of Adaptive Immunity: Tumor Antigen Vaccines, Adjuvants, and Dendritic Cells  
  *Nina Bhardwaj, MD, PhD*
  • Adoptive T-Cell Therapy of Cancer  
  *Cassian Yee, MD*
  • Tumor-Targeting Monoclonal Antibodies  
  *Louis M. Weiner, MD*
  • Immune Checkpoint Modulation  
  *Jedd D. Wolchok, MD, PhD* - Chair  
  • Panel Question and Answer

**Session Title:** On the Shoulders of Giants: Prostate Cancer Therapy—How We Got Here and Where We Are Going  
**Session Type:** Extended Education Session  
**Track:** Professional Development  
**Time:** 1:00 PM - 3:15 PM  
**Location:** S406

• Welcome & Introductions  
  *Albert C. Lockhart, MD* - Chair
  • Case Study Presentation & Discussion  
  *Jeffrey Melson Clarke, MD*
  • Lecture: Hormonal Manipulation for Prostate Cancer  
  *Howard I. Scher, MD*
  • Case Study Presentations & Discussion  
  *Daniel G. Stover, MD*
Lecture: Immunotherapy for Prostate Cancer

Celestia S. Higano, MD, FACP

Open to Audience Questions/Panel Discussion

Session Title: Tumor Genomic Profiling and Its Application to Personalized Medicine: Looking to the Future
Session Type: Extended Education Session
Track: Tumor Biology
Time: 1:00 PM - 3:15 PM
Location: S100bc

- Future Visions for Integrating Tumor Biology into Treatment
  Trever Grant Bivona, MD, PhD - Chair

- Looking Forward: Application of Genomics to Guiding Clinical Investigation
  Paul Workman, BSc, PhD, DSc

- Evolving Technologies in Somatic Tumor Genetics
  Elaine Mardis, PhD

- Homologous Recombination: Target, Predictive Biomarker, Prognostic Biomarker
  Christine S. Walsh, MD

- Therapeutic Dissection of Lung Cancer: One "Slice" at a Time
  Charles M. Rudin, MD, PhD

- Panel Question and Answer

Session Title: Central Nervous System Tumors
Session Type: Poster Highlights Session
Track: Central Nervous System Tumors
Time: 1:00 PM - 5:45 PM
Display and Networking Time: 1:00 PM - 4:00 PM
Display and Networking Location: E354b
Discussion Time: 4:30 PM - 5:45 PM
Discussion Location: E450

- Chair
  Timothy Francis Cloughesy, MD

- Chair
  Andrew B. Lassman, MD

- Board 1

- PD1 and PD-L1 expression in glioblastoma. (Abstract 2011)
  Anna Sophie Berghoff
Board 2
• Association of tumor-infiltrating lymphocytes with brain edema and overall survival in brain metastases. (Abstract 2012)
  Matthias Preusser
Board 3
• Results of comprehensive molecular profiling of gliomas and the potential therapeutic implications. (Abstract 2013)
  Santosh Kesari
Board 4
• Do host factors determine long-term survival in glioblastoma? A genome/transcriptome profiling study by the German Glioma Network. (Abstract 2014)
  Michael Weller
Board 5
• MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial. (Abstract 2015)
  Ghazaleh Tabatabai
Board 6
• MGMT gene promoter methylation in plasma of glioma patients receiving temozolomide. (Abstract 2016)
  Riccardo Soffietti
Board 7
• Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial. (Abstract 2017)
  Benedikt Wiestler
Board 8
• Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma. (Abstract 2018)
  Bart Neyns
Board 9
• Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma. (Abstract 2019)
  Patrick Y. Wen
Board 10
• Panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. (Abstract 2020)
  Eudocia Quant Lee
Board 11
• A phase 1 study evaluating ABT-414 in combination with temozolomide (TMZ) for subjects with recurrent or unresectable glioblastoma (GBM). (Abstract 2021)
  Hui Kong Gan
  Board 12

• Can average-risk medulloblastoma adult patients be treated with radiotherapy and plus chemotherapy? (Abstract 2022)
  Enrico Franceschi
  Board 14

• A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma. (Abstract 2023)
  Nicholas A. Butowski
  Board 15

• Primary malignant brain tumours (PMBT) in phase I studies: Barriers to treatment and patient outcomes. (Abstract 2024)
  Scheryll Paula Alken
  Board 16

• Results of stage 1 of the oparatic trial: A phase I study of olaparib in combination with temozolomide in patients with relapsed glioblastoma. (Abstract 2025)
  Anthony J. Chalmers
  Board 17

• Targeting glioma-initiating cells in GBM: ABTC-0904, a randomized phase 0/II study targeting the Sonic Hedgehog-signaling pathway. (Abstract 2026)
  Andrew E. Sloan
  Board 18

• Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results. (Abstract 2027)
  Andrew David Norden
  Board 19

• A multicenter randomized study comparing temozolomide (TMZ) versus TMZ-plus-bevacizumab (BEV) before standard treatment in unresectable glioblastoma (GBM) patients (p): The GENOM 009 study by the GEINO group. (Abstract 2028)
  Carmen Balana
  Board 20

• Phase 1/2 study of investigational hypoxia-targeted drug, TH-302, and bevacizumab (bev) in recurrent glioblastoma (GBM) following bev failure. (Abstract 2029)
  Andrew Jacob Brenner
  Board 21

• Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902). (Abstract 2030)
  Evanthia Galanis
Board 22
• Phase I study of plerixafor and bevacizumab in recurrent high-grade glioma. (Abstract 2031)
  *Katrina H. Smith*

Board 23
• Predictive factors of bevacizumab efficacy in relapsed glioblastoma patients. (Abstract 2032)
  *Patrizia Farina*

Board 24
• Venous thromboembolism (VTE) and glioblastoma. (Abstract 2033)
  *Jacob Joseph Mandel*

Board 25
• Joint modeling of longitudinal health-related quality of life (HRQoL) data and survival. (Abstract 2034)
  *Divine Ewane Ediebah*

Board 26
• Prospective assessment of neurocognitive outcomes in children and young adults with progressive/residual benign and low-grade brain tumors treated with high-precision conformal or conventional radiotherapy: Results of a randomized clinical trial. (Abstract 2035)
  *Rakesh Jalali*

• Biomarker Discovery and Application in Neuro-oncology
  *Howard Colman, MD, PhD*

• Molecularly Targeted Agents in Neuro-oncology: I
  *Fabio Massaiti Iwamoto, MD*

• Molecularly Targeted Therapies in Neuro-oncology: II
  *Louis B. Nabors, MD*

• Measuring Quality of Life in Neuro-oncology
  *Tobias Walbert, MD, PhD*

• Panel Question and Answer

**Session Title:** Developmental Therapeutics: Clinical Pharmacology and Experimental Therapeutics  
**Session Type:** Poster Highlights Session  
**Track:** Developmental Therapeutics  
**Time:** 1:00 PM - 5:45 PM

Display and Networking Time: 1:00 PM - 4:00 PM  
Display and Networking Location: E354b  
Discussion Time: 4:30 PM - 5:45 PM  
Discussion Location: E Arie Crown Theater
Co-Chair  
Luis A. Diaz, MD

Co-Chair  
Thehang H. Luu, MD

Board 27

Activity of TGR-1202, a novel once-daily PI3Kd inhibitor, in patients with relapsed or refractory hematologic malignancies. (Abstract 2513)  
Howard A. Burris

Board 28

A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors. (Abstract 2514^)  
Hendrik-Tobias Arkenau

Board 29

Glyco-optimized trastuzumab-GEX, a novel anti-HER2 monoclonal antibody with ADCC activity: A phase I clinical study in patients with HER2-positive tumors. (Abstract 2515)  
Hellmut Samonigg

Board 30

Phase 1 study of REGN1400 (anti-ErbB3) combined with erlotinib or cetuximab in patients (pts) with advanced non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck cancer (SCCHN). (Abstract 2516)  
Kyriakos P. Papadopoulos

Board 31

A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer. (Abstract 2517)  
Kerry Lynn Reynolds

Board 32

Phase 1 trial of MM-151, a novel oligoclonal anti-EGFR antibody combination in patients with refractory solid tumors. (Abstract 2518)  
Christopher Hanyoung Lieu

Board 33

A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer. (Abstract 2519)  
Seock-Ah Im

Board 34

Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors. (Abstract 2520^)  
Yung-Jue Bang

Board 35
• Results of the first-in-human phase I trial assessing MSC2156119J (EMD 1214063), an oral selective c-Met inhibitor, in patients (pts) with advanced solid tumors. (Abstract 2521^)
  Gerald Steven Falchook
  Board 36

• A phase 1b study of combined angiogenesis blockade with nesvacumab, a selective monoclonal antibody (MAb) to angiopoietin-2 (Ang2) and ziv-aflibercept in patients with advanced solid malignancies. (Abstract 2522)
  Kyriakos P. Papadopoulos
  Board 37

• Evaluation of CNS and peripheral antitumor activity of ANG1005 in patients with brain metastases from breast tumors and other advanced solid tumors. (Abstract 2523)
  Nancy U. Lin
  Board 38

• A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors. (Abstract 2524)
  Gerald Steven Falchook
  Board 40

• Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors. (Abstract 2525)
  Manuel Hidalgo
  Board 41

• A phase 1 first-in-human study of XMT-1107, a polymer-conjugated fumagillol derivative, in patients (pts) with advanced solid tumors. (Abstract 2526)
  Johanna C. Bendell
  Board 42

• A phase 1 dose-escalation study of BBI503, a first-in-class cancer stemness kinase inhibitor in adult patients with advanced solid tumors. (Abstract 2527)
  Scott Andrew Laurie
  Board 43

• A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas. (Abstract 2528^)
  Jeffrey R. Infante
  Board 44

• A phase I study of DMOT4039A, an antibody-drug conjugate (ADC) targeting mesothelin (MSLN), in patients (pts) with unresectable pancreatic (PC) or platinum-resistant ovarian cancer (OC). (Abstract 2529)
  Colin D. Weekes
  Board 45
• A phase 1b study of the cancer stem cell inhibitor BBI608 administered with paclitaxel in patients with advanced malignancies. (Abstract 2530)
  
  Matthew Hitron  
  Board 46  

• ProGem1: A phase I/II study of a first-in-class nucleotide, Acelarin, in patients with advanced solid tumors. (Abstract 2531)
  
  Essam Ahmed Ghazaly  
  Board 47  

• First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results. (Abstract 2532)
  
  Herbert Hurwitz  
  Board 48  

• VE-BASKET, a first-in-kind, phase II, histology-independent "basket" study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m). (Abstract 2533^)
  
  David Michael Hyman  
  Board 49  

• Next-generation sequencing (NGS) in 936 patients (pts) with advanced cancers to prospectively guide clinical trial selection: The Sarah Cannon Research Institute (SCRI) experience. (Abstract 2534)
  
  Todd Michael Bauer  
  Board 50  

• Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors. (Abstract 2535)
  
  Lillian L. Siu  
  Board 51  

• Risks and benefits of phase I liver dysfunction studies: Should patients with severe liver dysfunction be included in these trials? (Abstract 2536)
  
  Selena Juarez Stuart  
  Board 52  

• A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. (Abstract 2537)
  
  Morten Mau-Soerensen  
  Board 52  

• Targeting the ErB Family and PI3K Pathway
  
  Razelle Kurzrock, MD  

• Cross Talk between MET and VEGF Pathways
  
  Michael L. Maitland, MD, PhD  

• Innovative Targets in Drug Development
  
  Alex A. Adjei, MD, PhD
• Profiling and Patient Selection for Early-Phase Trials
  *Shivaani Kummar, MD*

• Panel Question and Answer

**Session Title:** Genitourinary (Nonprostate) Cancer  
**Session Type:** Poster Highlights Session  
**Track:** Genitourinary Cancer  
**Time:** 1:00 PM - 5:45 PM  
Display and Networking Time: 1:00 PM - 4:00 PM  
Display and Networking Location: S102  
Discussion Time: 4:30 PM - 5:45 PM  
Discussion Location: S100bc

• Co-Chair  
  *Ana M. Molina, MD*

• Co-Chair  
  *Neeraj Agarwal, MD*

• Comprehensive molecular profiling of urothelial bladder cancer at the DNA, RNA, and protein levels: A TCGA project. (Abstract 4509)  
  *John N. Weinstein*

• Association of somatic *ERCC2* mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (Abstract 4510)  
  *Jonathan E. Rosenberg*

• Somatic copy number abnormalities (SCNAs) and mutations in PI3K/AKT pathway as prognostic factors for overall survival (OS) in platinum-treated locally advanced or metastatic urothelial tumors. (Abstract 4511)  
  *Joaquim Bellmunt*

• Comparative effectiveness of gemcitabine plus cisplatin (GC) versus methotrexate, vinblastine, doxorubicin, plus cisplatin (MVAC) as neoadjuvant therapy for muscle-invasive bladder cancer (MIBC). (Abstract 4512)  
  *Matt D. Galsky*

• Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase II study. (Abstract 4513)  
  *Elizabeth R. Plimack*
• Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors. (Abstract 4514)
  Guru Sonpavde
Board 6

• Molecular profiling of testicular cancer. (Abstract 4515)
  Carsten Bokemeyer
Board 7

• Tumor genomic mutation profiling of germ cell tumors using "Profile". (Abstract 4516)
  Elizabeth O'Donnell
Board 8

• Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT). (Abstract 4517)
  Yago Nieto
Board 9

• Impact of long-term serum platinum on neuro- and ototoxicity, cardiovascular disease, and hypogonadism in testicular cancer survivors. (Abstract 4518)
  Line veronika Hjelle
Board 10

• Association of higher institutional volume with improved overall survival in clinical stage III testicular cancer: Results from the National Cancer Data Base (1998-2011). (Abstract 4519)
  Claudio Jeldres
Board 11

• A prospective observational study of metastatic renal cell carcinoma (mRCC) prior to initiation of systemic therapy. (Abstract 4520)
  Brian I. Rini
Board 12

• Outcomes of treatment cessation in select metastatic renal cell carcinoma (mRCC) patients. (Abstract 4521)
  Kriti Mittal
Board 13

• A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN). (Abstract 4522)
  Adriana L. Alvarez
Board 14

• High-dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR). (Abstract 4523)
  Michael Morse
Board 15
• Long-term survival in unfavorable-risk mRCC patients treated with a combination of autologous immunotherapy (AGS-003) plus sunitinib. (Abstract 4524^)
  Asim Amin

Board 17

• A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT). (Abstract 4525)
  Thomas Powles

Board 18

• PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors. (Abstract 4526)
  Andre Poisl Fay

Board 19

• CGH array and matching gene expression profiling for identification of distinct molecular variants among type II papillary renal cell carcinomas. (Abstract 4527)
  Laurence Albiges

Board 20

• Genotype correlations with blood pressure and efficacy outcomes from the randomized phase III AXIS trial of second-line axitinib versus sorafenib in metastatic renal cell carcinoma. (Abstract 4528)
  Bernard J. Escudier

Board 21

• Loss of BAP1 and PBRM1 expression in non-clear cell renal cell carcinomas compared to clear cell renal cell carcinomas. (Abstract 4529)
  Thai Huu Ho

Board 22

• Association of loss of BAP1 expression in cell renal cell carcinomas with PDL1 expression. (Abstract 4530)
  Richard Wayne Joseph

Board 23

• Identification and validation of predictive biomarkers (BM) for everolimus (EVE) in metastatic renal cell carcinoma: Analysis of 442 patients on RECORD-3. (Abstract 4531)
  Martin Henner Voss

Board 24

• Prognostic and predictive tumor-based biomarkers in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (IFN) with or without bevacizumab (Bev): Results from CALGB (Alliance) 90206. (Abstract 4532)
  Harriet M. Kluger

Board 25
• VEGF and VEGFRs polymorphisms analysis in advanced renal cell carcinoma tissues: Is heterogeneity ever the answer? (Abstract 4533)  
  
  Maristella Bianconi

• Neoadjuvant Chemotherapy and Biomarkers in Muscle-Invasive Bladder Cancer  
  
  Petros Grivas, MD, PhD

• Back to the Future  
  
  Peter Albers, MD

• Renal Cell Carcinoma: New Therapeutic Approaches  
  
  Tim Eisen, MB, PhD, FRCP

• Placing Biomarker Studies in Renal Cell Carcinoma in a Clinical Context  
  
  Manuela Schmidinger, MD

• Panel Question and Answer

---

**Session Title:** Lymphoma and Plasma Cell Disorders  
**Session Type:** Poster Highlights Session  
**Track:** Lymphoma and Plasma Cell Disorders  
**Time:** 1:00 PM - 5:45 PM  
Display and Networking Time: 1:00 PM - 4:00 PM  
Display and Networking Location: S405  
Discussion Time: 4:30 PM - 5:45 PM  
Discussion Location: S406

• Co-Chair  
  
  Steven M. Horwitz, MD

• Co-Chair  
  
  Sagar Lonial, MD

  Board 1

• CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma. (Abstract 8521)  
  
  Peter Martin

  Board 2

• Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. (Abstract 8522)  
  
  Matthew Steven Davids
Board 3
- U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881). (Abstract 8523)
  
  Paul M. Barr

Board 4
- A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab. (Abstract 8524)
  
  Owen A. O'Connor

Board 5
- A phase 1b study in cutaneous T-cell lymphoma (CTCL) with the novel topically applied skin-restricted histone deacteylase inhibitor (HDAC-i) SHP-141. (Abstract 8525)
  
  Youn H. Kim

Board 6
- Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL). (Abstract 8526)
  
  Anastasios Stathis

Board 7
- G-PCNSL-SG-1 randomized phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma: Long-term follow up. (Abstract 8527)
  
  Agnieszka Korfel

Board 8
- 10-year remission rates following rituximab (R) and FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) with interferon (IFN) maintenance in indolent lymphoma: Results of a randomized study. (Abstract 8528)
  
  Loretta J. Nastoupil

Board 9
- Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab (R-InO) versus chemotherapy for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL). (Abstract 8529)
  
  Nam H. Dang

Board 10
- Updated results of the FOLL05 phase III trial from the Fondazione Italiana Linfomi comparing R-CVP, R-CHOP, and R-FM in patients with advanced follicular lymphoma. (Abstract 8530)
  
  Stefano Luminari

Board 11
• Long-term results of the phase III GITMO/FIL trial of CHOP-R versus R-HDS plus autograft in high-risk follicular lymphoma (FL) at diagnosis. (Abstract 8531)
  Corrado Tarella
  Board 12

• A phase I trial of SAR650984, a CD38 monoclonal antibody, in relapsed or refractory multiple myeloma. (Abstract 8532)
  Thomas G. Martin
  Board 13

• Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. (Abstract 8533)
  Torben Plesner
  Board 14

• Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). (Abstract 8534)
  Jacob Laubach
  Board 15

• A phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone (QUAD) in relapsed and/or refractory multiple myeloma (MM). (Abstract 8535^)
  David H. Vesole
  Board 16

• Phase I trial of pomalidomide (P) in patients (pts) with relapsed and/or refractory (R/R) Waldenström's macroglobulinemia (WM). (Abstract 8536)
  Sheeba K. Thomas
  Board 17

• Optimizing induction and pretransplant consolidation for myeloma: Results of Myeloma XI, a phase III trial comparing different IMiDs. (Abstract 8537)
  Charlotte Pawlyn
  Board 18

• Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma. (Abstract 8538)
  Muzaffar H. Qazilbash
  Board 19

• Individualized therapy of relapsed or refractory myeloma with targeted agents. (Abstract 8539)
  Christoph Johann Heuck
  Board 20

• Ikaros expression levels to predict response and survival following pomalidomide and dexamethasone in multiple myeloma (MM). (Abstract 8540)
  Yuan Xiao Zhu
Board 21
• Utility of restaging bone marrow biopsy (BMB) in PET-negative patients with diffuse large B-cell lymphoma (DLBCL) with bone marrow involvement. (Abstract 8541)
  *Amie Elissa Jackson*

Board 22
• Net antitumoral immunity and the predictive power of conventional prognosticators in diffuse large B-cell lymphoma. (Abstract 8542)
  *Colm Keane*

Board 23
• Role of surveillance imaging in the management of peripheral T-cell lymphomas. (Abstract 8543)
  *Tiffany Pool Ling Tang*

Board 24
• Value of surveillance studies for patients (pts) with stage I-II diffuse large B-cell lymphoma (DLBCL) in the rituximab (R) era. (Abstract 8544)
  *Susan M. Hiniker*

Board 25
• Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumor burden (HTB) indolent non-Hodgkin lymphoma (iNHL): A multicenter phase II study. (Abstract 8545)
  *Andrew M. Evens*

• New Therapeutic Strategies for Relapsed Lymphomas
  *Stephen Maxted Ansell, MD*

• Clinical and Historical Context of Updated Randomized Lymphoma Studies
  *Sonali M. Smith, MD*

• Early-Phase Studies of Novel Agents in Plasma Cell Disorders
  *Amit Balkrishna Agarwal, MD, PhD*

• Clinical and Historical Context for Updated Randomized Trials in Myeloma
  *Suzanne Lentzsch, MD, PhD*

• Panel Question and Answer

**Session Title:** Maintenance of Certification and Lifelong Learning Workshop  
**Session Type:** Extended Education Session  
**Track:** Professional Development  
**Time:** 1:00 PM - 4:30 PM  
**Location:** E451b

• 2013 American Board of Internal Medicine Update in Medical Oncology
  *Thomas E. Stinchcombe, MD - Chair*
Session Title: Grant Writing Workshop
Session Type: Extended Education Session
Track: Professional Development
Time: 1:00 PM - 5:00 PM
Location: S103

- Conquer Cancer Foundation Grants Program
  Dean Frohlich
- National Cancer Institute Training and Career Development Grants
  Ming Lei, PhD
- Choosing a Mentor and Obtaining Letters of Support
  Susan Blaney, MD
- Working with a Biostatistician
  Karla V. Ballman, PhD
- Grant Writing Pearls
  Mary L. Disis, MD
- What to Do When Your First Grant Application Is Rejected
  Heather L. McArthur, MD
- Mock Study Session Leader
  Eric Jay Small, MD - Chair
- Small Group Discussion Table Leader
  Bruno C. Medeiros, MD
- Small Group Discussion Table Leader
  Dawn L. Hershman, MD, MS
- Small Group Discussion Table Leader
  N. Lynn Henry, MD, PhD
- Small Group Discussion Table Leader
  Kathleen A. Cooney, MD
- Small Group Discussion Table Leader
  Gary K. Schwartz, MD
- Small Group Discussion Table Leader
  Wells A. Messersmith, MD
Session Title: 50 Years of Fluorouracil, Radiation, and Surgery: What We've Learned, Recent Advances, and How to Treat Patients Today

Session Type: Education Session

Track: Gastrointestinal (Colorectal) Cancer

Time: 2:45 PM - 4:00 PM

Location: E Arie Crown Theater

- Medical Oncology Advances in the Last 50 Years: Focusing on the Most Recent Data in the Last Year
  - Alan P. Venook, MD - Chair

- Radiation Oncology Advances: Including the Role of Short-Course Radiation Therapy and Definitive Chemoradiation Therapy for Rectal Cancer
  - Joel E. Tepper, MD

- Surgical Advances: Including Total Mesorectal Excision, Laparoscopic Procedures, and Robotic Surgery
  - Martin R. Weiser, MD

- Panel Question and Answer

Session Title: Frontiers in Precision Medicine: Practical Application of Genomic Tools in Breast Cancer Management

Session Type: Education Session

Track: Breast Cancer

Time: 2:45 PM - 4:00 PM

Location: E Hall D1

- Genomics 101: Introduction to and Definitions of Current Genomic Tools in Breast Cancer
  - Jorge Reis-Filho, MD, PhD - Chair

- Current Use of Genomics in Clinical Practice: What Is Useful, What Is Not, and How to Communicate Results to Patients
  - Banu Arun, MD

- What's on the Horizon? Future Application of Genomics in Breast Cancer
  - Fabrice Andre, MD, PhD

- Panel Question and Answer
**Session Title:** Head and Neck Cancer: The Best of the Rest  
**Session Type:** Education Session  
**Track:** Head and Neck Cancer  
**Time:** 2:45 PM - 4:00 PM  
**Location:** E450  
- Best of AACR  
  *Ezra E.W. Cohen, MD - Chair*  
- Best of ASTRO  
  *Brian O'Sullivan, MD*  
- Best of the Multidisciplinary Head and Neck Symposium  
  *David Raben, MD*  
- Panel Question and Answer

**Session Title:** Personalizing Therapy for Elderly Patients with Lymphoid Malignancies  
**Session Type:** Education Session  
**Track:** Geriatric Oncology  
**Time:** 2:45 PM - 4:00 PM  
**Location:** E253  
- Optimizing Therapy for Lymphoma: How to Integrate Age, Function, and Comorbidity  
  *Paul A. Hamlin, MD - Chair*  
- Selecting Therapy for Chronic Lymphocytic Leukemia in Older Patients: When to Start?  
  *Valentin Goede, MD*  
- Multiple Myeloma in the Older Patient: How to Navigate Treatment Options  
  *Tanya Marya Wildes, MD, MSCI*  
- Panel Question and Answer

**Session Title:** Primary Central Nervous System Lymphoma: Past, Present, and Future - Ticketed Session  
**Session Type:** Meet the Professor Session  
**Track:** Central Nervous System Tumors  
**Time:** 2:45 PM - 4:00 PM  
**Location:** E451a  
- The Role of Interventions for Primary Central Nervous System Lymphoma: Radiation, Surgery, and Transplant  
  *Michael Weller, MD*
• Optimizing Multiagent Therapy and Long-term Outcomes in Primary Central Nervous System Lymphoma  
  *Lisa Marie DeAngelis, MD*

**Session Title:** Can We Find Common Ground? Stakeholder Perspectives on Value in Cancer Care  
**Session Type:** Extended Education Session  
**Track:** Health Services Research  
**Time:** 3:45 PM - 6:00 PM  
**Location:** S100a

• Value in Cancer Care: What's the Problem?  
  *Neal J. Meropol, MD - Chair*

• The Patient Perspective  
  *Diane Blum, MSW*

• Defining Value: An ASCO Initiative  
  *Lowell E. Schnipper, MD*

• Using Value for Coverage  
  *Lee Nisley Newcomer, MD*

• Industry Perspective: Drug Development, Costs, and Return on Investment  
  *Gregory P. Rossi, PhD*

• How Should Oncologists Become Value-Based Providers?  
  *Ezekiel J. Emanuel, MD, PhD*

• Panel Question and Answer

**Session Title:** Why I Love the Career I Chose  
**Session Type:** Extended Education Session  
**Track:** Professional Development  
**Time:** 3:45 PM - 6:00 PM  
**Location:** S404

• Career in Academia  
  *Daniel F. Hayes, MD*

• Career in Practice  
  *Melissa S. Dillmon, MD*

• Career in Hybrid: Academia and Practice  
  *Johanna C. Bendell, MD*

• Career in Industry  
  *Mace L. Rothenberg, MD*

• Career in Government
Session Title: Special Session for Program Directors and Key Clinical Faculty: Intragenerational Learning- Teaching Millennial Learners and Practical Use of Milestones
Session Type: Education Session
Track: Professional Development
Time: 4:00 PM - 6:00 PM
Location: E350

- Welcome and Introduction  
  Frances A. Collichio, MD - Chair
- Presentation of the 2014 Excellence in Teaching Award  
  Sandra M. Swain, MD, FACP
- Excellence in Teaching Award  
  Michael H. Levy, MD, PhD
- How Do We Teach and Engage Millennial Learners?  
  Alexandra P. Wolanskyj, MD
- Implementing the Curricular and Subspecialty Milestones  
  Nathan M. Shumway, DO

Session Title: 50 Years of Lung Cancer: The Current Status of Therapy for Non-Small Cell Lung Cancer—Adjuvant Therapy, Chemoradiotherapy, and Systemic Treatment
Session Type: Education Session
Track: Lung Cancer
Time: 4:30 PM - 5:45 PM
Location: E Hall D1

- Reviewing Adjuvant Therapy in Non-Small Cell Lung Cancer: Clinical Trials and Data for Use of Targeted Agents in This Setting  
  Heather A. Wakelee, MD
- Stage III Non-Small Cell Lung Cancer: Selection of Regimen and New Approaches  
  Karen Kelly, MD
- 50 Years of Progress in Non-Small Cell Lung Cancer  
  Martin J. Edelman, MD - Chair
- Panel Question and Answer
**Session Title:** From Signaling Pathways to Therapeutics: What Are the Targets?  
**Session Type:** Education Session  
**Track:** Tumor Biology  
**Time:** 4:30 PM - 5:45 PM  
**Location:** E354a

- Taking on Challenging Targets: Making MYC Druggable  
  *Andrei Goga, MD, PhD - Chair*  
- The Paradox of RAF  
  *Roger Lo, MD, PhD*  
- Autophagy as a Therapeutic Target in Solid Tumors  
  *Jayanta Debnath, MD*  
- Panel Question and Answer

**Session Title:** Updates in Prostate Cancer Risk and Prevention  
**Session Type:** Education Session  
**Track:** Cancer Prevention/Epidemiology  
**Time:** 4:30 PM - 5:45 PM  
**Location:** S504

- PCPT and SELECT Overview and Update  
  *Ian Murchie Thompson, MD - Chair*  
- The Role of Obesity, Nutrition, and Vitamins in Prostate Cancer Risk and Prevention  
  *Alan Kristal, DrPH*  
- Inflammation and Prostate Cancer Risk  
  *Elizabeth A. Platz, ScD, MPH*  
- Panel Question and Answer

**Session Title:** Why Functional Age Matters: Care for Older Patients with Prostate and Bladder Cancer  
**Session Type:** Education Session  
**Track:** Geriatric Oncology  
**Time:** 4:30 PM - 5:45 PM  
**Location:** E253

- Optimizing Treatment for Older Men with Advanced Prostate Cancer  
  *Supriya Gupta Mohile, MD, MS - Chair*  
- Treatment Goals and Options for Older Patients with Bladder Cancer  
  *Matt D. Galsky, MD*
• Coordination of Care: Integrating a Multidisciplinary Geriatric Care Model
  *William Dale, MD, PhD*

• Panel Question and Answer

**Session Title:** A New Age of Immunotherapy in Genitourinary Tumors? - Ticketed Session
**Session Type:** Meet the Professor Session
**Track:** Genitourinary Cancer
**Time:** 4:30 PM - 5:45 PM
**Location:** E451a

• New Age of Immunotherapy in Prostate Cancer
  *Eric Jay Small, MD*

• New Age of Immunotherapy in Kidney and Bladder Cancer
  *Charles G. Drake, MD, PhD*